OPG/RANKL: Role and therapeutic target in osteoporosis;OPG/RANKL: Implication et cible thérapeutique dans l'ostéoporose

Medecine/Sciences

Volumn 24, Issue 1, 2008, Pages 105-109

  Marie, Pierre ^a   Halbout, Philippe ^b  

^a CNRS   (France)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 13; INTERLEUKIN 18; INTERLEUKIN 4; OSTEOCLAST DIFFERENTIATION FACTOR;

ARTICLE; CELL DIFFERENTIATION; HYPERCALCEMIA; IN VITRO STUDY; OSTEOPOROSIS; PATHOGENESIS; PROTEIN EXPRESSION;

EID: 38849097103     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/2008241105     Document Type: Article

References (30)

1. Marie PJ. Différenciation, fonction et régulation de l'ostéoblaste. Med Sci (Paris) 2001 ; 12 : 1252-9.
2. Marie P, Debiais F, Cohen-Solal M, de Vernejoul MC. De nouveaux facteurs contrôlent le remodelage osseux. Rev Rhumatol 2000 ; 67 : 260-7.
3. Suda T, Takahashi N, Udagawa N, et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999 ; 20 : 345-57.
4. Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med 2001 ; 79 : 243-53.
5. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003 ; 423 : 337-42.
6. Tanaka S, Nakamura K, Takahasi N, Suda T. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol Rev 2005 ; 208 : 30-49.
7. Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 2006 ; 12 : 17-25.
8. Huang JC, Sakata T, Pfelger LL, et al. PTH differentially regulates expression of RANKL and OPG. J Bone Miner Res 2004 ; 19 : 235-44.
9. Spencer GJ, Utting JC, Etheridge SL, et al. Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. J Cell Sci 2006 ; 119 : 1283-96.
10. Holmen SL, Zylstra CR, Mukherjee A, et al. Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem 2005 ; 280 : 21162-8.
11. Kostenuik PJ, Shaloub V. Osteoprotegerin : a physiological and pharmacological inhibitor of bone resorption. Curr Pharm Des 2001 ; 7 : 613-35.
12. Kostenuik PJ. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol 2005 ; 5 : 618-25.
13. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004 ; 292 : 490-5.
14. Seeman E, Delmas P. Bone quality-the material and structural basis of bone strength and fragility. N Engl J Med 2006 ; 354 : 2250-61.
15. Khosla S, Riggs BL. Pathophysiology of age-related bone loss and osteoporosis. Endocrinol Metab Clin North Am 2005 ; 34 : 1015-30.
16. Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. Science 2000 ; 289 : 1508-14.
17. Nakamichi Y, Udagawa N, Kobayashi Y, et al. Osteoprotegerin reduces the serum level of receptor activator of NF-kappaB ligand derived from osteoblasts. J Immunol 2007 ; 178 : 192-200.
18. Eghbali-Fatourechi G, Khosla S, Sanyal A, et al. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003 ; 111 : 1221-30.
19. Martin TJ. Current, new and emerging anti-resorptive drugs; antibody blockade of RANKL action. BoneKey-Osteovision 2006 ; 3 : 42-6.
20. Riggs BL, Parfitt AM. Drugs used to treat osteoporosis : the critical need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res 2005 ; 20 : 177-84.7.
21. Hofbauer LC, Khosla S, Dunstan CR, et al. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 1999 ; 140 : 4367-70.
22. Kim YH, Kim GS, Jeong-Hwa B. Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression. Exp Mol Med 2002 ; 34 : 145-51.
23. Locklin RM, Khosla S, Turner RT, Riggs BL. Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. J Cell Biochem 2003 ; 89 : 180-90.
24. Bolon B, Carter C, Daris M, et al. Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis. Mol Ther 2001 ; 3 : 197-205.
25. Bekker PJ, Holloway D, Nakanishi A, et al. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2001 ; 16 : 348-60.
26. McClung MR, Lewieki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006 ; 354 : 821-31.
27. Marie PJ. Strontium ranelate : a dual mode of action rebalancing bone turnover in favour of bone formation. Curr Opin Rheumatol 2006 ; 18 : S11-5.
28. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004 ; 350 : 459-68.
29. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis : treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005 ; 90 : 2816-22.
30. Brennan T, Rybchyn MS, Conigrave AD, Mason RS. Strontium ranelate effect on proliferation and OPG expression in osteoblasts. Calcif Tissue Int 2006 ; 78 : S1-129.